Position in XENE
as of Jun 30, 2026
· filed Jul 29, 2026
Position Value
$5,891,739
+$1,953,647 QoQ
Shares Held
97,610
+44.1% QoQ
Ownership
0.101%
of shares outstanding
% of Portfolio
0.03%
of 13F equity value
Holder Rank
#109
of 313 holders
Holding Since
Jun 2020
23 quarters on record
Voting authority
Sole 100%
Shared 0%
None 0%
Common Shares in XENE Over Time
Shares Held
Position Value (USD)
Position in Biotechnology
Healthcare · as of Jun 30, 2026ALPS ADVISORS INC holds $213,436,831 across 115 Biotechnology names. XENE ranks #4 (2.8% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | RPRX |
Royalty Pharma plc
|
315,335 | $17,680,833 | |
| 2 | APGE |
Apogee Therapeutics, Inc.
|
62,523 | $8,298,677 | |
| 3 | CGON |
CG Oncology, Inc.
|
89,218 | $6,338,938 | |
| 4 | XENE |
Xenon Pharmaceuticals Inc.
This page
|
97,610 | $5,891,739 | |
| 5 | ORKA |
Oruka Therapeutics, Inc.
|
61,014 | $5,806,702 | |
| 6 | DNTH |
Dianthus Therapeutics, Inc. /DE/
|
55,281 | $5,388,791 | |
| 7 | TVTX |
Travere Therapeutics, Inc.
|
93,981 | $5,339,060 | |
| 8 | DFTX |
Definium Therapeutics, Inc.
|
110,388 | $5,192,651 |
All Filings in XENE
Export CSV
23 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $5,891,739 | 97,610 | Shares | Defined | 2026-07-29 | |
| 2026-03-31 | $3,938,092 | 67,723 | Shares | Defined | 2026-05-08 | |
| 2025-12-31 | $2,837,195 | 63,302 | Shares | Defined | 2026-02-12 | |
| 2025-09-30 | $1,497,595 | 37,300 | Shares | Defined | 2025-11-05 | |
| 2025-06-30 | $1,295,194 | 41,380 | Shares | Defined | 2025-08-11 | |
| 2025-03-31 | $1,856,388 | 55,332 | Shares | Defined | 2025-04-30 | |
| 2024-12-31 | $2,416,601 | 61,648 | Shares | Defined | 2025-02-13 | |
| 2024-09-30 | $2,243,656 | 56,989 | Shares | Defined | 2024-11-12 | |
| 2024-06-30 | $2,294,678 | 58,853 | Shares | Defined | 2024-08-13 | |
| 2024-03-31 | $2,290,260 | 53,200 | Shares | Defined | 2024-05-14 | |
| 2023-12-31 | $2,338,926 | 50,780 | Shares | Defined | 2024-02-14 | |
| 2023-09-30 | $1,617,441 | 47,349 | Shares | Defined | 2023-11-14 | |
| 2023-06-30 | $1,798,835 | 46,723 | Shares | Defined | 2023-08-14 | |
| 2023-03-31 | $1,486,287 | 41,528 | Shares | Defined | 2023-05-10 | |
| 2022-12-31 | $1,670,688 | 42,371 | Shares | Defined | 2023-02-14 | |
| 2022-09-30 | $1,225,919 | 33,959 | Shares | Defined | 2022-11-14 | |
| 2021-12-31 | $1,865,090 | 59,702 | Shares | Defined | 2022-02-09 | |
| 2021-09-30 | $770,341 | 50,415 | Shares | Defined | 2021-11-15 | |
| 2021-06-30 | $1,004,716 | 53,959 | Shares | Defined | 2021-08-11 | |
| 2021-03-31 | $1,133,624 | 63,331 | Shares | Defined | 2021-05-07 | |
| 2020-12-31 | $972,846 | 63,254 | Shares | Defined | 2021-02-03 | |
| 2020-09-30 | $493,987 | 44,624 | Shares | Defined | 2020-11-05 | |
| 2020-06-30 | $598,208 | 47,704 | Shares | Defined | 2020-08-05 | |
| No filing history on record for this holder in this stock. | ||||||